Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s traded shares stood at 0.7 million during the latest session, with the company’s beta value hitting 0.80. At the last check today, the stock’s price was $6.34, to imply an increase of 0.24% or $0.01 in intraday trading. The RXRX share’s 52-week high remains $15.74, putting it -148.26% down since that peak but still an impressive 21.61% since price per share fell to its 52-week low of $4.97. The company has a valuation of $1.85B, with an average of 4.04 million shares in intraday trading volume over the past 10 days and average of 4.89 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Recursion Pharmaceuticals Inc (RXRX), translating to a mean rating of 2.50. Of 3 analyst(s) looking at the stock, 0 analyst(s) give RXRX a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 2 recommend it as a Buy.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
After registering a 0.24% upside in the latest session, Recursion Pharmaceuticals Inc (RXRX) has traded red over the past five days. The 5-day price performance for the stock is -3.13%, and -7.91% over 30 days. With these gigs, the year-to-date price performance is -35.65%. Short interest in Recursion Pharmaceuticals Inc (NASDAQ:RXRX) saw shorts transact 62.58 million shares and set a 12.15 days time to cover.
The extremes give us $6 and $12 for target low and target high price respectively. As such, RXRX has been trading -89.27% off suggested target high and 5.36% from its likely low.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
Looking at statistics comparing Recursion Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Recursion Pharmaceuticals Inc (RXRX) shares are -19.07% down over the last 6 months, with its year-to-date growth rate lower than industry average at 0.00% against 17.60%.
An assessment of the company’s 5-year growth patterns shows that annual earnings shrunk an estimated -43.41% for the past 5-year period. While 2024 is set for a 1.11% return in earnings, projections for the next 5 years are at 12.00% annually.
RXRX Dividends
Recursion Pharmaceuticals Inc has its next earnings report out on 2024-Nov-07. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX)’s Major holders
Recursion Pharmaceuticals Inc insiders hold 4.45% of total outstanding shares, with institutional holders owning 90.02% of the shares at 94.21% float percentage. In total, 90.02% institutions holds shares in the company, led by ARK INVESTMENT MANAGEMENT LLC. As of 2024-06-30, the company held over 28.14 million shares (or 11.924% of shares), all amounting to roughly $211.07 million.
The next major institution holding the largest number of shares is BAILLIE GIFFORD & CO with 26.59 million shares, or about 11.266% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $199.42 million.
We also have ARK ETF Tr-ARK Innovation ETF and ARK ETF Tr-ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Recursion Pharmaceuticals Inc (RXRX) shares. Going by data provided on Sep 30, 2024, ARK ETF Tr-ARK Innovation ETF holds roughly 17.83 shares. This is just over 6.39% of the total shares, with a market valuation of $114.54 million. Data from the same date shows that the other fund manager holds a little less at 12.71, or 4.55% of the shares, all valued at about 81.63 million.
